Andrew Branagan
Massachusetts General Hospital · Yale University
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andrew Branagan as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:37 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT07791498 · Teclistamab In Waldenstrom's MacroglobulinemiaMassachusetts General Hospital · not yet recruiting · Waldenstrom's Macroglobulinemia · principal investigator
- Ph2NCT06561347 · Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WMMassachusetts General Hospital · recruiting · Waldenstrom Macroglobulinemia · principal investigator
- N/ANCT04830046 · Covid-19 Vaccine Responsiveness in MM and WaldenstromMassachusetts General Hospital · completed · Multiple Myeloma, Waldenstrom Macroglobulinemia, Immune System Disorder · principal investigator
- Ph2NCT02566265 · Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy PatientsYale University · completed · Influenza, Multiple Myeloma, Waldenstrom's Macroglobulinemia · principal investigator
- Ph1NCT02267733 · Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing In Gammopathy PatientsYale University · completed · Influenza, Gammopathy · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:37 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:37 UTC. The ranking covers the 200 most relevant of 19 PubMed records, and a shared surname and initials can bring in a namesake. All 19 on PubMed
- Polymorphisms in FcgammaRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia.J Clin Oncol · 2005195 citationsRCR 3.8
- Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.Clin Cancer Res · 2007140 citationsRCR 2.7
- Extended rituximab therapy in Waldenström's macroglobulinemia.Ann Oncol · 2005137 citationsRCR 3.0
- Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.Ann Oncol · 2004118 citationsRCR 2.7
- 115 citationsRCR 3.0
- Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.Clin Cancer Res · 200998 citationsRCR 2.2
- 97 citationsRCR 2.3
- Venetoclax in Previously Treated Waldenström Macroglobulinemia.J Clin Oncol · 202290 citationsRCR 5.3
- 48 citationsRCR 2.7
- Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial.Clin Lymphoma Myeloma Leuk · 201740 citationsRCR 1.4